Endogenous renal 11β-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension

Hypertension

Volumn 27, Issue 2, 1996, Pages 197-201

  Takeda, Yoshiyu ^a   Miyamori, Isamu ^a   Iki, Kazuhiro ^a   Inaba, Satoru ^a   Furukawa, Kenji ^a   Hatakeyama, Haruhiko ^a   Yoneda, Takashi ^a   Takeda, Ryoyu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

adrenal cortex hormones; hydroxysteroid dehydrogenase; kidney; renin

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY FACTOR; ALDOSTERONE; ENZYME INHIBITOR; HYDROCORTISONE; POTASSIUM; RENIN; SODIUM; TETRAHYDROCORTISOL; TETRAHYDROCORTISONE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN CELL; KIDNEY MICROSOME; MALE; PRIORITY JOURNAL; SODIUM RESTRICTION; URINARY EXCRETION;

EID: 0030068190     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.2.197     Document Type: Article

References (34)

1. Monder C, Shackleton CHL. 11β-Hydroxysteroid dehydrogenase: fact or fancy? Steroids. 1984;44:383-417.
2. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, Rosler A, Bradlow HL, New MI. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab. 1979;49:757-764.
3. Stewart PM, Valentino R, Wallace AM, Burt D, Shackleton CHL, Edwards CRW. Mineralocorticoid activity of liquorice: 11-β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987;2:821-824.
4. Stewart PM, Wallace AM, Atherden SM, Shearing CH, Edwards CRW. Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11β-hydroxysteroid dehydrogenase activity in man. Clin Sci. 1990;78:49-54.
5. Walker BR, Stewart PM, Shackleton CHL, Padfield PL, Edwards CRW. Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol. 1993;39:221-227.
6. Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Iki K, Takeda R. Decreased activity of 11β-hydroxysteroid dehydrogenase in mesenteric arteries of Dahl salt-sensitive rats. Life Sci. 1994;54:1343-1349.
7. Takeda Y, Yoneda T, Miyamori I, Gathiram P, Takeda R. 11β-Hydroxysteroid dehydrogenase activity in mesenteric arteries of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1993;20:627-631.
8. +-dependent isoform of 11β-hydroxysteroid dehydrogenase. J Biol Chem. 1994;269:25959-25962.
9. Morris DJ, Semafuko WEB, Latif SA, Vogel B, Grimes CA, Sheff MF. Detection of glycyrrhetinic acid-like factors (GALFs) in human urine. Hypertension. 1982;20:346-360.
10. Walker BR, Aggarwal ILA, Stewart PM, Padfield PL, Edwards CRW. Endogenous inhibitors of 11β-hydroxysteroid dehydrogenase in hypertension. J Clin Endocrinol Metab. 1995;80:529-533.
11. Walker BR, Williamson PM, Brown MA, Honour JW, Edwards CRW, Whitworth JA. 11β-Hydroxysteroid dehydrogenase and its inhibitors in hypertensive pregnancy. Hypertension. 1995;25:626-630.
12. Benediktsson R, Walker BR, Edwards CRW. Cellular selectivity of aldosteronc: role of 11 beta-hydroxysteroid dehydrogenase. Curr Opin Nephrol Hypertens. 1995;4:41-46.
13. Kaplan NM. Primary hypertension: pathogenesis. In: Retford DC, ed. Clinical Hypertension. 6th ed. Baltimore, Md: Williams & Wilkins: 1994:47-108.
14. Lebel M, Schalekamp MA, Beevers DG. Sodium and the reninangiolensin system in essential hypertension and mineralocorticoid excess. Lancet. 1974;2:308-310.
15. Gomez-Sanchez CE, Holland OB, Upcavage R. Urinary free 19-nor-deoxycorticosterone and deoxycorticosterone in human hypertension. J Clin Endocrinol Metab. 1985;60:234-238.
16. Takeda R, Morimoto S, Uchida K, Hashiba T, Kigoshi T, Honjo A, Fujimura A. Aldosterone responsiveness to angiotensin II after sodium restriction in subjects with low renin essential hypertension. Clin Exp Hypertens A. 1982;4:937-949.
17. Takeda Y, Miyamori I, Takeda R, Lewicka S, Vecsei P. Effect of sodium restriction on urinary excretion of 19-noraldosterone and 18,19-dihydroxycorticosterone, newly identified mineralocorticoids in man. J Clin Endocrinol Metab. 1992;74:1195-1197.
18. Takeda Y, Miyamori I, Iki K, Takeda R, Vecsei P. Urinary excretion of 19-noraldosterone, 18,19-dihydroxycorticosterone and 18-hydroxy-19-norcorticosterone in patients with aldosterone-producing adenoma or idiopathic hyperaldosteronism. Acta Endocrinol. 1992;126:484-488.
19. Takeda Y, Karayalcin U, Miyamori I, Takeda R. Influence of 3-hydroxy-3-methyglutaryl coenzymc A reductase inhibitor, pravastatin, on corticosteroid metabolism in patients with heterozygous familial hypercholesterolemia. Horm Res. 1991;36:75-77.
20. Takeda R, Morimoto S, Uehida K, Miyamori I. Changes in plasma renin activity and plasma aldosterone in the induced paralytic attack of thyrotoxic periodic paralysis. Acta Endocrinol. 1976;82:715-727.
21. Iki K, Miyamori I, Hatakeyama H, Yoneda T, Takeda Y, Takeda R, Dai QI. The activities of 5β-reductase and 11β-hydroxysteroid dehydrogenase in essential hypertension. Steroids. 1994;59:656-660.
22. Stewart PM, Murry BA, Mason JI. Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab. 1994;79:480-484.
23. Barker DJP, Bull AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of hypertension in adult life. BMJ. 1990;301:259-262.
24. Edwards CRW, Benediktsson R, Lindsay RS, Seckl JR. Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet. 1993;341:355-357.
25. Iwai J, Dahl LK, Knudsen KD. Genetic influence on the reninangiotensin system. Circ Res. 1973;32:678-684.
26. Baba K, Mulrow PJ, Franco-Saenz R, Rapp JP. Suppression of adrenal renin in Dahl salt-sensitive rats. Hypertension. 1986;8:1149-1153.
27. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Takeda R. Gene expression of 11β-hydroxysteroid dehydrogenase in the mesenteric arteries of genetically hypertensive rats. Hypertension. 1994;23:577-580.
28. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CHL, Funder JW, New MI. A mutation in the HSDB2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995;80:2263-2266.
29. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme dehydrogenase. Nat Genet. 1995;10:394-399.
30. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. Evidenee of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in subjects with untreated essential hypertension. Hypertension. 1995;25:67-70.
31. Ross EJ. Biological role of aldosterone in homeostasis. In: Ross EJ, ed. Aldosterone and Aldosteronism. London, UK: Lloyd-Luke Ltd; 1975:192-207.
32. Riddle MC, McDaniel PA. Acute reduction of renal 11β-hydroxysteroid dehydrogenase activity by several antinatriuretic stimuli. Metabolism. 1993;42:1370-1374.
33. Escher G, Meyer KV, Vishwanath BS, Frey BM, Frey FJ. Furosemide inhibits 11β-hydroxysteroid in vitro and in vivo. Endocrinology. 1995;136:1759-1765.
34. Riddle MC, McDaniel PA. Renal 11β-hydroxysteroid dehydrogenase activity is enhanced by ramipril and captopril. J Clin Endocrinol Metab. 1994;78:830-834.